June 26, 2020 News by Marisa Wexler, MS NICE Does Not Favor Adding Mayzent to NHS England for Active SPMS TheĀ National Institute for Health and Care Excellence (NICE) is recommending againstĀ Mayzent (siponimod) as a treatment for active secondary progressive multiple sclerosis (SPMS) in the U.K., because its cost-effectiveness relative to an existing treatment for these patients is not known. NICE’s draft guidance for Mayzent is open…
February 4, 2019 News by Iqra Mumal, MSc MS Trust Opens ‘Advanced MS Champions’ Program to Bring Better Care to UK Patients Healthcare specialists forĀ multiple sclerosis patients in the U.K. with advanced disease and challenging needs are getting support and recognition through a new program from the MS Trust. Called theĀ Advanced MS Champions Programme, it will recognize six MS specialist “champions” working with people with advanced MS, and their families…
December 3, 2018 News by Mary Chapman Mumford & Sons Bassist Helps UK MS Society Tackle Patient Loneliness with New Exhibit A musician, a member of Parliament, and the Multiple Sclerosis Society in the United Kingdom have joined forces to increase awareness on the social isolation that often accompanies multiple sclerosisĀ (MS). The campaign grew from the society’s research, which found that up to 60 percent of MS patients, or…
April 13, 2017 News by Alice MelĆ£o, MSc Scottish Medicines Consortium Approves Zinbryta for NHS Treatment of RRMS Patients in Scotland The United KingdomāsĀ National Institute for Health and Care Excellence (NICE)Ā last month recommendedĀ Zinbryta (daclizumab)Ā to treatĀ relapsing-remitting multiple sclerosis (RRMS)Ā in England and Wales. On April 10,Ā Scotland receivedĀ Scottish Medicines Consortium (SMC)Ā approval for the National Health Service (NHS) to prescribe ZinbrytaĀ as a treatment for RRMS. Zinbryta is…
March 30, 2017 News by Patricia Silva, PhD Hope, But No Cheers Yet, Voiced by MS Groups in Europe and Canada Waiting on Own Ocrevus Decision American patient groupsĀ and neurologists haveĀ clearly been giving Ocrevus (ocrelizumab) plenty of attention since news of its approval landed, as a sweep of U.S. reaction to the FDA’s decision showed. But what is happening elsewhere in regard to this firstĀ treatment for both primary progressive and relapsing multiple sclerosis (MS)?…
October 18, 2016 News by Patricia Silva, PhD MS Society Awards Almost $220K to Research into Myelin Repair and Renewal The MS SocietyĀ in the United Kingdom awarded Ā£177,930 (about $217,800) to Dr.Ā Sassan Hafizi, a researcher at University of Portsmouth, to investigate the potentially beneficial role of a central nervous system molecule,Ā called Gas6, in repairingĀ the myelin damage seen in patients with multiple sclerosis (MS) . Hafizi and Dr. Arthur…
October 5, 2016 News by Patricia Silva, PhD MS Trust to Oppose NICE Plan to Reject Zinbryta as MS Therapy in Health System for England, Wales The Multiple Sclerosis (MS) Trust isĀ expressing its disappointment at the recent committee decision ofĀ theĀ National Institute for Health and Care ExcellenceĀ (NICE)Ā to not recommendĀ Zinbryta (daclizumab) be made available as a therapy to MSĀ patients using the public health system in England and Wales. NICE’sĀ preliminary recommendationĀ was based on a review of…
November 19, 2014 News by Isaura Santos ‘Treat Me Right’ MS Society Campaign Shortlisted For Award TheĀ Treat Me RightĀ campaign from the MSĀ SocietyĀ in the UK was recentlyĀ shortlistedĀ for this year’s voluntary sector campaignĀ Public Affairs Award. The campaign was launched in April 2014 during MS Week to raise awareness for the importance of providing the right treatment at the right moment…